ClinicalTrials.gg
RecruitingNCT05492344Updated Oct 15, 2026

Personalized Mechanical Ventilation Guided by UltraSound in Patients With Acute Respiratory Distress Syndrome

An interventional study of Personalized ventilation and Standard care in ARDS, Human, Lung Ultrasound and Mechanical Ventilation, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 11 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.
Updated Oct 15, 2026First site in China1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
538
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Respiratory Distress Syndrome with a site in Denmark — 3 open to participants now, 3 under way, 1 of them phase 3. Respiratory Distress Syndrome · Denmark.

Started
2022
with 1 other
No phase
2 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 12 studies in Respiratory Distress Syndrome with a site in Denmark, this one is one of 2 that started in 2022, is one of 2 with no phase, and was the 9th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

3 of the 12 studies in Respiratory Distress Syndrome with a site in Denmark are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Respiratory Distress Syndrome with a site in Denmark, or all of them as a file.
02

Study summary

Rationale Acute respiratory distress syndrome (ARDS) is a frequent cause of hypoxemic respiratory failure with a mortality rate of approximately 30%. The identification of ARDS phenotypes, based on focal or non-focal lung morphology, can be helpful to better target mechanical ventilation strategies of individual patients. Lung ultrasound (LUS) is a non-invasive tool that can accurately distinguish 'focal' from 'non-focal' lung morphology. The investigators hypothesize that LUS-guided personalized mechanical ventilation in ARDS patients will lead to a reduction in 90-day mortality compared to conventional mechanical ventilation.

Read the detailed description

Objective The aim of this study is to determine if personalized mechanical ventilation based on lung morphology assessed by LUS leads to a reduced mortality compared to conventional mechanical ventilation in ARDS patients.

Study design The PEGASUS study is an investigator-initiated multicenter randomized clinical trial (RCT) with a predefined feasibility and safety evaluation after a pilot phase.

Study population This study will include 538 consecutively admitted invasively ventilated adult intensive care unit (ICU) patients with moderate or severe ARDS. There will be a predefined feasibility and safety evaluation after inclusion of the first 80 patients.

Intervention Patients will receive a LUS exam within 12 hours after diagnosis of ARDS to classify lung morphology as focal or non-focal ARDS. Immediately after the LUS exam patients will be randomly assigned to the intervention group, with personalized mechanical ventilation, or the control group, in which patients will receive standard care.

Main study parameters/endpoints The primary endpoint is all cause mortality at day 90 (diagnosis of ARDS considered as day 0). Secondary outcomes are mortality at 28 days, ventilator free days (VFD) at day 28, ICU length of stay, ICU mortality, hospital length of stay, hospital mortality and number of complications (VAP, pneumothorax and need for rescue therapy). After a pilot phase, feasibility of LUS, correct interpretation of LUS images and correct application of the intervention within the safe limits of mechanical ventilation is evaluated to inform a stop-go decision.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness Patient burden and risks are low as the ventilation methods in this study are already commonly used in ICU practice; the collection of general data from hospital charts and (electronic) medical records systems causes no harm to the patients; LUS is not uncomfortable.

03

Conditions studied

  • ARDS, Human
  • Lung Ultrasound
  • Mechanical Ventilation
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to a participating ICU,
  • invasively ventilated and
  • fulfil the Berlin criteria for moderate or severe ARDS.

Exclusion criteria

Exclusion Criteria:

  • Age under 18,
  • participation in other interventional studies with conflicting endpoints,
  • conditions in which LUS is not feasible or possible (e.g. subcutaneous emphysema, morbid obesity or wounds),
  • mechanical ventilation for longer than 7 consecutive days in the past 30 days,
  • history of ARDS in the previous month,
  • body-mass index higher than 40 kg/m²,
  • intracranial hypertension,
  • broncho-pleural fistula,
  • chronic respiratory diseases requiring long-term oxygen therapy or respiratory support,
  • pulmonary fibrosis with a vital capacity \< 50% (severe or very severe),
  • previously randomized in the PEGASUS study
  • ECMO
  • patients who receive invasive ventilation in home setting due to a neurological disease
  • pregnant patients
  • patients who are moribund or facing end of life and
  • no .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
538 participants (estimated)

Study arms

  • Experimental
    Personalized ventilation

    If a patient is assigned to the intervention group, ventilator settings will be adjusted based on the lung morphology (focal or non focal) results of the lung ultrasound.

    Other: Personalized ventilation

  • Active comparator
    Standard care

    Patients assigned to the control group will be ventilated according to the current standard of care.

    Other: Standard care

Interventions

  • OtherPersonalized ventilation

    Patients who are randomized for personalized ventilation with FOCAL ARDS will receive the following ventilator settings: * Positive end-expiratory pressure (PEEP) ≤ 9 cm water (H2O) * Tidal volume: 6 to 8 mL/kg predicted body weight (PBW) * Daily prone positioning LUS will be repeated every 48-72 hours in supine position for the focal ARDS patients to assess whether they have developed non-focal ARDS during admission. In that case, patients will from then on be treated according non-focal personalized treatment protocol. Patients who are randomized for personalized ventilation with Non-FOCAL ARDS will receive the following ventilator settings: * PEEP ≥ 15 cm H2O * Tidal volume: 4 to 6 mL/kg PBW * Daily recruitment maneuver

  • OtherStandard care

    Patient who are randomized in the control group will receive standard care * Tidal volume: 6 mL/kg PBW * PEEP and FiO2 according to the low PEEP and high fraction of inspired oxygen (FiO2) table of the AlVEOLI study * Prone positioning if the Partial Pressure of Oxygen (PaO2) /FiO2 ratio is \< 150 mmHg

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Any death during ICU- or hospital-stay at day 90

    Time frame: 90 days after inclusion

Secondary outcomes

  1. All-cause mortality

    Any death during ICU- or hospital-stay at day 28

    Time frame: 28 days after inclusion

  2. Ventilator free days

    Duration of ventilation in survivors

    Time frame: 28 days after inclusion

  3. ICU length of stay

    Length of stay in the intensive care unit

    Time frame: 90 days after inclusion

  4. ICU mortality

    Mortality in the ICU

    Time frame: 90 days after inclusion

  5. Hospital length of stay

    Length of stay in the hospital

    Time frame: 90 days after inclusion

  6. Hospital mortality

    Mortality in the hospital

    Time frame: 90 days after inclusion

  7. Number of patients with Complications

    Ventilator associated pneumonia and pneumothorax

    Time frame: 90 days after inclusion

  8. Number of patients with Adjunctive therapies

    Extracorporeal membrane oxygenation (ECMO), recruitment, prone position

    Time frame: 90 days after inclusion

  9. Number of patients with Rescue therapies

    Inhaled vasodilators, airway pressure release ventilation

    Time frame: 90 days after inclusion

07

Study locations

10 of 11 sites recruiting
08

References and documents

Publications

  • Sinnige JS, Smit MR, Alam MJ, Chowdhury MNH, Costa V, de Castro HSMB, Daszuta D, Filippini DFL, Ghose A, de Grooth HJ, Hein L, Hermans G, Hildebrandt T, Itenov TS, Ischaki E, Klompmaker P, Laffey J, McMahon A, McNicholas B, Mousa A, Paulus F, Pedersen UG, Pellegrini M, Pezzuto M, Povoa P, Pierrakos C, Pisani L, Roca O, Schultz MJ, Spadaro S, Szuldrzynski K, Theodorou E, Tuinman PR, Wamberg CA, Zimatore C, Bos LDJ; PEGASUS investigators. Personalized mechanical ventilation guided by lung ultrasound in patients with ARDS: a pilot phase of a randomized clinical trial. Intensive Care Med Exp. 2025 Dec 22;13(1):135. doi: 10.1186/s40635-025-00835-8. PubMed 41423518 ↗
  • Sinnige JS, Smit MR, Ghose A, de Grooth HJ, Itenov TS, Ischaki E, Laffey J, Paulus F, Povoa P, Pierrakos C, Pisani L, Roca O, Schultz MJ, Szuldrzynski K, Tuinman PR, Zimatore C, Bos LDJ; PEGASUS investigators. Personalized mechanical ventilation guided by ultrasound in patients with acute respiratory distress syndrome (PEGASUS): study protocol for an international randomized clinical trial. Trials. 2024 May 7;25(1):308. doi: 10.1186/s13063-024-08140-7. PubMed 38715118 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Aug 2027, 59 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 59 months is above that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2022
First posted
Aug 8, 2022
StartActual
Aug 9, 2022
Primary completionEst.
Aug 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in China
Show site
  • West China Hospital · Chengdu, China
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    1 site added — first site in China
    Show site
    • West China Hospital · Chengdu, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05492344
Responsible party
Prof. Dr. Marcus J. Schultz (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Aug 8, 2022
Start date
Aug 9, 2022
Primary completion
Aug 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Jante S Sinnige, M.D.
Contact
j.s.sinnige@amsterdamumc.nl
+31637405311
Marry R Smit, Dr.
Contact
m.r.smit@amsterdamumc.nl
+3120 5666339
Lieuwe DJ Bos, Dr.
principal investigator · Amsterdam UMC, location AMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion